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Abstract 
BACKGROUND: Rosacea is a common, chronic disorder that can present with a variety of cutaneous or ocular 
manifestations. Skin involvement primarily affects the central face, with findings such as persistent centrofacial 
redness, papules, pustules, flushing, telangiectasia, and phymatous skin changes. The pathways that lead to the 
development of rosacea are not well understood. The relationship of pyoderma faciale (also known as rosacea 
fulminans) to rosacea also is uncertain. We aimed to write this article with the aim of showing how a pregnant 
patient who has been aggravated by the degree of lesions on the face during the first trimester of pregnancy is 
treated and to show what is in the literature in this issue.  
CASE REPORT: A 22-year-old woman complained of painful erythema, papules and pustules on the face. She 
had fever and malaise during the sixth week of her first pregnancy and a history of the mild eruption and 
seborrhea before her pregnancy with flaring over the preceding 4 weeks. Dermatologic examination revealed red 
erythema of all involved facial areas; the lesions consisted of papules, pustules and nodules. The case was 
diagnosed as rosacea fulminans (pyoderma faciale) by these findings. In the literature, there are some effective 
therapeutic options such as retinoids, tetracyclines, antiandrogenic contraceptives, and dapsone and these were 
not used because they are contraindicated in pregnancy. Amoxicillin-clavulanic acid 1 gr/day, wet compresses, 
and a fusidic acid cream were started. After the activity of the disease had been suppressed for 10 days, antibiotic 
was stopped, and the other treatment options were applied topically for the next month. One month after 
cessation of treatment, the lesions had disappeared with only mild erythema remaining. There was minimally 
flushing on the face and no telangiectasia.  
CONCLUSION: In conclusion, there is no substantial evidence as to the mechanism by which pregnancy may 
trigger this conditioner whether the gender of the fetus influences the development of rosacea fulminans, but is 
generally accepted that hormonal changes in pregnancy play an important role. The pathogenesis of rosacea 
fulminans remains uncertain, but it is obvious that the further basic and clinical research is required to optimise 
the management of this rare facial dermatosis. 
 
 
 
 
 
 
 
 
Introduction 
 
Rosacea is a common, chronic disorder that 
can present with a variety of cutaneous or ocular 
manifestations.  
Skin involvement primarily affects the central 
face, with findings such as persistent centrofacial 
redness, papules, pustules, flushing, telangiectasia, 
and phymatous skin changes. The pathways that lead 
to the development of rosacea are not well 
understood [1] [2].  
Proposed contributing factors include 
abnormalities in innate immunity, inflammatory 
reactions to cutaneous microorganisms, ultraviolet 
damage, and vascular dysfunction. 
The relationship of pyoderma faciale (also 
known as rosacea fulminans) to rosacea also is 
uncertain [3]. Patients present with intensely 
inflammatory, purulent facial plaques and nodules with 
draining sinuses on a background of erythema. A 
history of rosacea may or may not be present. Young 
women are most commonly affected. 
Because pregnancy is also a process in which 
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the immune system is weakened, cases of rosacea 
exacerbated in pregnancy, namely rosacea fulminans, 
have been reported in the literature. 
We aimed to write this article to show how a 
pregnant patient who has been aggravated by the 
degree of lesions on the face during the first trimester 
of pregnancy is treated and to show what is in the 
literature in this issue. 
 
 
Case Report 
 
A 22-year-old woman complained of painful 
erythema, papules and pustules on the face. She had 
fever and malaise during the sixth week of her first 
pregnancy and a history of the mild eruption and 
seborrhea before her pregnancy with flaring over the 
preceding 4 weeks. Dermatologic examination 
revealed red erythema of all involved facial areas; the 
lesions consisted of papules, pustules and nodules 
(Figure 1A, 1B).  
  
  
Figure 1: Patient with rosacea fulminans (pyoderma faciale). A, B = 
before the treatment; C, D = after the treatment 
 
There were no comedons or telangiectasia 
and no pathologic findings upon systemic 
examination. Laboratory studies revealed a white 
blood cell count of 14600/mm, haemoglobin level of 
13.8 g/dl, CRP level of 6 mg/dl. Cultures for bacterial 
pathogens were negative. Hormonal tests were not 
performed. The case was diagnosed as rosacea 
fulminans (pyoderma faciale) by these findings. In the 
literature, there are some effective therapeutic options 
such as retinoids, tetracyclines, antiandrogenic 
contraceptives, and dapsone and these were not used 
because they are contraindicated in pregnancy. 
Amoxicillin-clavulanic acid 1 gr/day, wet compresses, 
and a fusidic acid cream were started. After the 
activity of the disease had been suppressed for 10 
days, antibiotic was stopped, and the other treatment 
options were applied topically for the next month. 
One month after cessation of treatment, the 
lesions had disappeared with only mild erythema 
remaining. There was minimally flushing on the face 
and no telangiectasia (Figure 1C, 1D). 
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Discussion 
 
In 2002, the National Rosacea Society 
assembled an expert committee to develop a standard 
classification system for rosacea.  
The committee established four distinct 
subtypes of rosacea: erythematotelangiectatic, 
papulopustular, phymatous, and ocular rosacea [3]. 
Since then, increasing knowledge of the 
pathophysiology of rosacea has favoured a view of 
rosacea as a consistent multivariate disease process 
with multiple clinical manifestations rather than distinct 
subtypes of disease [4].  
Following recommendations from the Global 
ROSacea COnsensus (ROSCO) Panel supporting the 
use of phenotype-based, rather than a subtype-based, 
approach to the diagnosis and classification of 
rosacea, the National Rosacea Society expert 
committee released an update supporting a similar 
approach [4] [5].  
The cutaneous histopathologic findings in 
rosacea are nonspecific, and skin biopsies are rarely 
indicated. When the diagnosis is uncertain, biopsies 
may be performed to rule out other disorders or to 
provide support for a diagnosis of granulomatous 
rosacea. No serologic studies are useful for diagnosis. 
Specimens from erythematous facial skin 
exhibiting centrofacial erythema and telangiectasias 
usually show dilation of superficial blood vessels and 
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a low-grade perivascular, lymphohistiocytic, 
inflammatory infiltrate with occasional plasma cells. 
Solar elastosis is often present. Histopathologic 
examination of papular lesions usually reveals 
prominent perivascular and perifollicular inflammatory 
infiltrates in the superficial and mid-dermis composed 
of lymphocytes, neutrophils, and plasma cells. 
Superficial accumulations of neutrophils are present in 
pustules. In contrast to acne vulgaris, inflammation 
often is more perivascular and extends well beyond 
the follicle [6].  
Rosacea fulminans was first described by 
O'Leary and Kierland in 1940 as ‘pyoderma faciale [7]. 
Plewig et al., Regarded the condition as an extreme 
form of rosacea and suggested that it be renamed 
‘rosacea fulminans’ in their report of twenty cases had 
been reported in the literature [8]. 
Rosacea fulminans is characterised by rapid 
onset, a fulminating course, strict localisation to the 
face, absence of comedones and absence of 
acneiform lesions on the chest or back. The 
characteristic lesions are superficial papulopustules 
and nodules combined with cyanotic erythema. 
The pathogenesis of rosacea fulminans is 
unknown, but severe emotional trauma (such as the 
death of a family member, divorce or an accident) is 
often blamed [7] [8]. 
Dermatologic conditions that may be 
exacerbated perimenstrually include acne vulgaris, 
rosacea, psoriasis, atopic eczema and urticaria. 
Hormonal changes resulting in increased cutaneous 
vascularity, seborrhea, and dermal oedema during the 
perimenstrual period resemble those of pregnancy 
and may be related to eruption or exacerbation of 
these diseases [9]. 
Massa and Su reported that 6 of 29 rosacea 
fulminans cases were associated with pregnancy [10]. 
In the series published by Plewig et al., 3 of 20 
patients had developed the disease during pregnancy 
[8]. Haugstvedt and Bjerke reported a flare-up of 
rosacea during pregnancy in 1998 [11]. 
In 2004, Lewis and colleagues first described 
a case of rosacea fulminans in pregnancy, and 
treatment options were mentioned for the first time in 
this publication [12].  
As we did not perform hormonal tests in our 
patient and there was no history of oral contraceptive 
use, it is not possible to state that pregnancy or oral 
contraceptive us may have been a triggering factor for 
rosacea fulminans in our patient. However, we agree 
with Plewig et al., [7]. That pregnancy can be 
considered an exacerbating factor for rosacea 
fulminans, and that hormonal factors may be a trigger 
for rosacea fulminans during pregnancy and in 
females taking oral contraceptive pills. 
In 2006, Ferahbaş and colleagues from 
Turkey, they issued a rosacea fulminans cases 
occurring in pregnancy and compiled the literature up 
to that time. They have treated this case with systemic 
corticosteroids and have continued to treat with topical 
metronidazole cream and have reported successful 
treatment [13]. 
In 2008, Cisse and colleagues reported that 
rosacea fulminans developed during the early period 
of a pregnancy obtained with IVF. In this case, 
hormonal treatments in IVF treatment have been 
shown to be the major cause of rosacea fulminans 
development [14]. 
In 2010, Jarrett and his colleagues identified 
three cases of rosacea fulminans in pregnancy and 
explained how this dermatological problem affected 
pregnancy outcomes [15]. 
In 2011, Morais e Silva FA and her colleagues 
published a case of rosacea fulminans in pregnancy 
that caused ocular perforation, and it states how 
serious the consequences may be [16]. In 2011, 
Fuentelsaz and colleagues treated rosacea fulminans 
case of pregnancy with azithromycin and achieved 
success. And they stated that the use of systemic 
corticosteroids is not an untreatable treatment [17]. In 
2014, Wollina U. made a better comprehension of the 
aetiology of rosacea fulminans and compiled recent 
publications on management [18]. Then, in 2015, 
Haenen CC and her colleagues treated a patient who 
had rosacea fulminans in pregnancy with 
erythromycin and was successful [19]. 
When both the treatment options are given in 
the literature, and the treatments mentioned in the 
dermatology books are compiled, early and 
aggressive treatment is recommended, yet pregnancy 
poses a therapeutic dilemma; the recognised effective 
treatments, including retinoids, tetracycline antibiotics, 
antiandrogenic contraceptives and dapsone are all 
contraindicated during pregnancy [12]. 
Isotretinoin has been associated with 
congenital anomalies; tetracyclines are associated 
with discolouration of the teeth and impaired bone 
growth, dapsone may cause neonatal haemolysis 
[12]. 
Metronidazole is not recommended before the 
second trimester and although erythromycin is 
considered safe it is not always effective because of 
resistance in some bacteria [12]. 
Erythromycin administration is usually a safe 
option in pregnancy, but it has been shown in the 
literature that erythromycin administration is more 
effective in cases with comedones and bacterial 
reoccurrence [12]. 
In our case, erythromycin was not 
administered because of the low incidence of 
comedones, as we have already mentioned, and the 
other options were directed. 
The use of systemic steroids can only be 
justified if the benefits outweigh the risks of 
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intrauterine growth retardation,  maternal diabetes 
mellitus and hypertension [12]. 
For these reasons, we do not consider the 
use of systemic steroids in our case. Since topical 
medicines are generally known not to damage the 
fetus during pregnancy, they have been tried in the 
treatment of our case. 
After taking other options that were not 
available in pregnancy, we also gave the patient 
topical fusidic acid and systemic penicillin antibiotics 
and found that there was a significant improvement. 
In conclusion, there is no substantial evidence 
as to the mechanism by which pregnancy may trigger 
this conditioner whether the gender of the fetus 
influences the development of rosacea fulminans, but 
is generally accepted that hormonal changes in 
pregnancy play an important role. In pregnancy, the 
use of topical drying compounds, surgical drainage, 
and topical and systemic antibiotics and 
corticosteroids have been reported, but the best 
practice remains inconclusive. 
We suggest a multidisciplinary approach with 
early diagnosis, shared obstetric and dermatology 
care and provision of emotional support to the mother. 
The pathogenesis of rosacea fulminans remains 
uncertain, but it is obvious that the further basic and 
clinical research is required to optimise the 
management of this rare facial dermatosis. 
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